Search Results - "ADENIS, A"

Masitinib in advanced gastrointestinal stromal tumor (GIST) after failure of imatinib: A randomized controlled open-label trial by Adenis, A., Blay, J.-Y., Bui-Nguyen, B., Bouché, O., Bertucci, F., Isambert, N., Bompas, E., Chaigneau, L., Domont, J., Ray-Coquard, I., Blésius, A., Van Tine, B.A., Bulusu, V.R., Dubreuil, P., Mansfield, C.D., Acin, Y., Moussy, A., Hermine, O., Le Cesne, A.

“…Masitinib is a highly selective tyrosine kinase inhibitor with activity against the main oncogenic drivers of gastrointestinal stromal tumor (GIST). Masitinib…”
Get full text

Continuation versus discontinuation of first-line chemotherapy in patients with metastatic squamous cell oesophageal cancer: A randomised phase II trial (E-DIS) by Adenis, A., Bennouna, J., Etienne, P.L., Bogart, E., Francois, E., Galais, M.P., Ben Abdelghani, M., Michel, P., Metges, J.P., Dahan, L., Conroy, T., Ghiringhelli, F., Drouillard, A., El Hajbi, F., Samalin, E., Hiret, S., Delaine-Clisant, S., Mariette, C., Penel, N., Piessen, G., Le Deley, M.C.

“…The role of chemotherapy has not been established in the treatment of metastatic squamous cell oesophageal cancer (mESCC). E-DIS is a discontinuation trial,…”
Get full text

Scabies in French Guiana: Quantitative and qualitative factors associated with therapeutic failure by Blaizot, R., Armanville, F., Michaud, C., Boceno, C., Dupart, O., Pansart, C., Niemetzky, F., Couppie, P., Nacher, M., Adenis, A., Chosidow, O., Duvignaud, A.

“…Background Strategies for the control of scabies should be adapted to local settings. Traditional communities in French Guiana have non‐Western conceptions of…”
Get full text

Influence of imatinib interruption and rechallenge on the residual disease in patients with advanced GIST: results of the BFR14 prospective French Sarcoma Group randomised, phase III trial by Patrikidou, A., Chabaud, S., Ray-Coquard, I., Bui, B.N., Adenis, A., Rios, M., Bertucci, F., Duffaud, F., Chevreau, C., Cupissol, D., Domont, J., Pérol, D., Blay, J.Y., Le Cesne, A.

“…We previously demonstrated that interruption of imatinib mesylate (IM) in responding patients (pts) with advanced gastrointestinal stromal tumours (GISTs)…”
Get full text

Stereotactic Radiotherapy of Hepatocellular Carcinoma: Preliminary Results by Louis, C., Dewas, S., Mirabel, X., Lacornerie, T., Adenis, A., Bonodeau, F., Lartigau, E.

“…Stereotactic radiotherapy (SRT) offers a treatment option for hepatocellular carcinoma (HCC) patients that are not eligible for surgery, embolization,…”
Get full text

Pathological response and safety of two neoadjuvant strategies with bevacizumab in MRI-defined locally advanced T3 resectable rectal cancer: a randomized, noncomparative phase II study by Borg, C., André, T., Mantion, G., Boudghène, F., Mornex, F., Maingon, P., Adenis, A., Azria, D., Piutti, M., Morsli, O., Bosset, J.F.

“…In T3 rectal cancer (RC), preoperative chemoradiotherapy [5-fluorouracil (5-FU–RT)] reduces local recurrences, but does not affect overall survival. New…”
Get full text

Health-related quality of life results from the PRODIGE 5/ACCORD 17 randomised trial of FOLFOX versus fluorouracil–cisplatin regimen in oesophageal cancer by Bascoul-Mollevi, C., Gourgou, S., Galais, M.-P., Raoul, J.-L., Bouché, O., Douillard, J.-Y., Adenis, A., Etienne, P.-L., Juzyna, B., Bedenne, L., Conroy, T.

“…A recent prospective randomised trial did not reveal significant differences in median progression-free survival between two chemoradiotherapy (CRT) regimens…”
Get full text

High prevalence of hepatitis B and syphilis in illegal gold miners in French Guiana by Douine, M., Schaub, R., Jardin, H., Adenis, A., Nacher, M., Hureau-Mutricy, L., Vreden, S., Mosnier, E., Pisoni, A., Tuaillon, E.

“…Viral hepatitis and syphilis remain important public health issues because of chronic forms and clinical complications. The omission of hard-to-reach and…”
Get full text

Tackling a worrisome rate of lost to follow-up among migrants with hepatitis B in French Guiana by Vo-Quang, E., Vignier, N., Adenis, A., Adriouch, L., Lucarelli, A., Guarmit, B, Nacher, M.

“…•LTFU remains prevalent among individuals with HBV infection.•Callback strategy to re-engage LTFU patients in HBV care proved feasible.•Lack of knowledge on…”
Get full text

Efficacy and safety of bevacizumab-based combination regimens in patients with previously untreated metastatic colorectal cancer: Final results from a randomised phase ii study of bevacizumab plus 5-fluorouracil, leucovorin plus irinotecan versus bevacizumab plus capecitabine plus irinotecan (FNCLCC ACCORD 13/0503 study) by Ducreux, M, Adenis, A, Pignon, J.-P, François, E, Chauffert, B, Ichanté, J.L, Boucher, E, Ychou, M, Pierga, J.-Y, Montoto-Grillot, C, Conroy, T

“…Abstract Background The combination of bevacizumab and bolus 5-fluorouracil, leucovorin and irinotecan is highly effective in patients with metastatic…”
Get full text

Sorafenib and irinotecan (NEXIRI) as second- or later-line treatment for patients with metastatic colorectal cancer and KRAS-mutated tumours: a multicentre Phase I/II trial by Samalin, E, Bouché, O, Thézenas, S, Francois, E, Adenis, A, Bennouna, J, Taieb, J, Desseigne, F, Seitz, J F, Conroy, T, Galais, M P, Assenat, E, Crapez, E, Poujol, S, Bibeau, F, Boissière, F, Laurent-Puig, P, Ychou, M, Mazard, T

“…Background: This trial evaluated the feasibility and efficacy of combined sorafenib and irinotecan (NEXIRI) as second- or later-line treatment of patients with…”
Get full text

The phase 3 KEYNOTE-181 study: pembrolizumab versus chemotherapy as second-line therapy for advanced esophageal cancer by Metges, J., François, E., Shah, M., Adenis, A., Enzinger, P., Kojima, T., Muro, K., Bennouna, J., Hsu, C., Moriwaki, T., Kim, S., Lee, S., Kato, K., Shen, L., Qin, S., Ferreira, P., Wang, R., Bhagia, P., Kang, S., Doi, T.

Get full text

An extended phase Ib study of epertinib, an orally active reversible dual EGFR/HER2 tyrosine kinase inhibitor, in patients with solid tumours by Arkenau, H.-T., Italiano, A., Mak, G., Toulmonde, M., Baird, R.D., Garcia-Corbacho, J., Plummer, R., Flynn, M., Forster, M., Wilson, R.H., Tosi, D., Adenis, A., Donaldson, K., Posner, J., Kawabata, I., Arimura, A., Deva, S., Spicer, J.

“…Dose-escalation of epertinib (S-222611), a new potent oral EGFR/HER2 inhibitor, has established a recommended daily dose of 800 mg in patients with solid…”
Get full text

A phase 3 study of chemotherapy + pembrolizumab versus chemotherapy + placebo as first-line therapy for patients with advanced esophageal or esophagogastric junction (E/EGJ) cancer: KEYNOTE-590 - Trial in progress by Kato, K., Shah, M., Enzinger, P., Bennouna, J., Shen, L., Adenis, A., Sun, J., Cho, B., Ozguroglu, M., Kojima, T., Kostorov, V., Hierro, C., Zhu, Y., Shah, S., Bhagia, P., Doi, T.

Get full text

Phase III KEYNOTE-590 study of chemotherapy + pembrolizumab versus chemotherapy + placebo as first-line therapy for patients (Pts) with advanced esophageal or esophagogastric junction (E/EGJ) cancer by Kato, K., Shah, M.A., Enzinger, P.C., Bennouna, J., Shen, L., Adenis, A., Sun, J.-M., Cho, B.C., Ozguroglu, M., Kojima, T., Kostorov, V., Hierro, C., Zhu, Y., Shah, S., Bhagia, P., Doi, T.

Get full text

A dose-escalating phase I of imatinib mesylate with fixed dose of metronomic cyclophosphamide in targeted olid tumours by Adenis, A, Ray-Coquard, I, Italiano, A, Chauzit, E, Bui-Nguyen, B, Blay, J-Y, Tresch-Bruneel, E, Fournier, C, Clisant, S, Amela, E Y, Cassier, P A, Molimard, M, Penel, N

“…Background: Preclinical findings suggest that imatinib mesylate (IM) and metronomic cyclophosphamide (MC) combination provides synergistic antiangiogenic…”
Get full text

Summary of Guidelines for Managing Histoplasmosis among People Living with HIV by Perez, Freddy, Caceres, Diego H, Ford, Nathan, Ravasi, Giovanni, Gomez, Beatriz L, Pasqualotto, Alessandro C, Hine, Paul, Adenis, Antoine A, Nacher, Mathieu, Chiller, Tom, Baddley, John, For The Guideline Development Group For Diagnosing And Managing Disseminated Histoplasmosis Among People Living With Hiv

“…Histoplasmosis is a frequent fungal opportunistic infection in people living with HIV (PLHIV), associated every year to a total of 5% to 15% of AIDS-related…”
Get full text

High prevalence of HPV infection in the remote villages of French Guiana: an epidemiological study by ADENIS, A., DUFIT, V., DOUINE, M., CORLIN, F., AYHAN, G., NAJIOULLAH, F., MOLINIE, V., BROUSSE, P., CARLES, G., LACOSTE, V., CESAIRE, R., NACHER, M.

“…Cervical cancer is the second most frequent cancer in women in French Guiana. Studies have shown that populations living in the remote areas of the interior…”
Get full text

Clinical value of circulating endothelial cell levels in metastatic colorectal cancer patients treated with first-line chemotherapy and bevacizumab by Malka, D., Boige, V., Jacques, N., Vimond, N., Adenis, A., Boucher, E., Pierga, J.Y., Conroy, T., Chauffert, B., François, E., Guichard, P., Galais, M.P., Cvitkovic, F., Ducreux, M., Farace, F.

“…We investigated whether circulating endothelial cells (CECs) predict clinical outcome of first-line chemotherapy and bevacizumab in metastatic colorectal…”
Get full text

A dose-escalating phase I of imatinib mesylate with fixed dose of metronomic cyclophosphamide in targeted solid tumours by ADENIS, A, RAY-COQUARD, I, CASSIER, P. A, MOLIMARD, M, PENEL, N, ITALIANO, A, CHAUZIT, E, BUI-NGUYEN, B, BLAY, J.-Y, TRESCH-BRUNEEL, E, FOURNIER, C, CLISANT, S, AMELA, E. Y

“…Preclinical findings suggest that imatinib mesylate (IM) and metronomic cyclophosphamide (MC) combination provides synergistic antiangiogenic activity on both…”
Get full text